AstraZeneca begins advanced trials for COVID-19 antibody medication

British pharmaceutical company AstraZeneca has commenced late-stage trials for its COVID-19 antibody drug. In an Oct. 9 statement, the company said that two tests for the AZD7442 long-acting antibody drug, involving 6,000 adult participants worldwide, will look at the medication’s ability to prevent COVID-19 symptoms. A subsequent trial to observe AZD7442’s use as a COVID-19 treatment, involving 4,000 volunteers, … Continue reading AstraZeneca begins advanced trials for COVID-19 antibody medication